The Shareholders Foundation announces that an investigation on behalf of investors of Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares was initiated over potential securities laws violations by Halozyme Therapeutics.
If you purchased shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO), you have certain options and you should contact the Shareholders Foundation at mail(at)shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Halozyme Therapeutics, Inc. (NASDAQ:HALO) concerning whether a series of statements by Halozyme Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Halozyme Therapeutics, Inc reported that its annual Total Revenue rose from over $42.33 million in 2012 to $54.80 million in 2013 while its Net Loss increased from $53.55 million to $83.48 million.
Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) grew from $4.82 per share in November 2012 to as high as $17.03 per share in January 2014.
Then on April 4, 2014, Halozyme Therapeutics, Inc. announced that as a result of a recommendation received on April 3,2014 from an independent Data Monitoring Committee (DMC), it is temporarily halting patient enrollment and dosing of PEGPH20 in an ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer.
Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) dropped from $11.77 per share on April 3, 2014 to $8.14 per share on April 4,2014 and declined to as low as $7.05 per share on April 14, 2014.
On April 28, 2014, NASDAQ:HALO shares closed at $7.22 per share.
Those who purchased shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO), have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Trevor Allen
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com